We believe in science minded people having high standards of quality and integrity and who want to grow to the limits of their abilities. At NovAliX, we nurture a culture that is goal-focused, team-oriented and self-managed. Reflecting NovAliX entrepreneurial spirit, management and employees are the company shareholders.

NovAliX has been established with the goal of providing industry researchers with knowledge and enabling capabilities in chemistry and biophysics. Since 2003, building on its world class academic legacy from Strasbourg University and IGBMC in the field of organic chemistry and structural biology, NovAliX has assembled a team of 120 highly talented scientists complemented by an outstanding platform in biophysics.

NovAliX development strategy combines organic growth with external opportunities with those sharing its human, scientific and entrepreneurial values.

Graffinity's fragment-based drug discovery platform combines a proprietary SPR imaging technology with a unique lead-like and fragment library. (Acquired by NovAliX in Oct. 2010)

NMRTEC founded by world class spectroscopist provides characterization studies for small molecules and biologics based on unique NMR technology platform. (Acquired by NovAliX in Jan. 2010)

Phytodia provides research services in phyto-bio-engineering and develops novel ingredients for nutraceutical and dermo-cosmetic companies. (Spun-off from NovAliX in Dec. 2006)

eNovalys develops novel chemoinformatics tools for chemistry data clustering and mining and a novel reaction prediction system. (Spun-off from NovAliX in Mar. 2009).

  Return to top